These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 8608502

  • 1. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S.
    Cancer; 1996 Apr 01; 77(7):1274-7. PubMed ID: 8608502
    [Abstract] [Full Text] [Related]

  • 2. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E.
    Eur J Clin Chem Clin Biochem; 1994 Mar 01; 32(3):189-99. PubMed ID: 7518259
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C, Mohn-Staudner A, Vetter H, Kokron O, Baumgartner G, Scheiner W, Zwick H, Koderhold G, Alth G, Dudczak R.
    Wien Klin Wochenschr; 1996 Mar 01; 108(15):467-72. PubMed ID: 8806188
    [Abstract] [Full Text] [Related]

  • 4. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P.
    J Exp Clin Cancer Res; 2000 Dec 01; 19(4):477-81. PubMed ID: 11277326
    [Abstract] [Full Text] [Related]

  • 5. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM.
    Anticancer Res; 2005 Dec 01; 25(3A):1773-8. PubMed ID: 16033098
    [Abstract] [Full Text] [Related]

  • 6. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA, Liu X, Tian XD, Wang W, Liang CY, Zhang T, Guo JT, Peng YH, Zhou NK.
    Chin Med J (Engl); 2011 Oct 01; 124(20):3244-8. PubMed ID: 22088515
    [Abstract] [Full Text] [Related]

  • 7. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Oct 01; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 8. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Oct 01; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 9. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E.
    Anticancer Res; 1999 Oct 01; 19(4C):3613-8. PubMed ID: 10629660
    [Abstract] [Full Text] [Related]

  • 10. [Tumor markers in lung cancer].
    Niho S, Shinkai T.
    Gan To Kagaku Ryoho; 2001 Dec 01; 28(13):2089-93. PubMed ID: 11791391
    [Abstract] [Full Text] [Related]

  • 11. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P, Riantawan P, Lebnak P, Getngern P.
    J Med Assoc Thai; 2000 Apr 01; 83(4):383-91. PubMed ID: 10808698
    [Abstract] [Full Text] [Related]

  • 12. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM, Sauer-Eppel H, Bruzdziak TH.
    Anticancer Res; 2007 Apr 01; 27(4A):1911-5. PubMed ID: 17649794
    [Abstract] [Full Text] [Related]

  • 13. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
    Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T.
    Cancer; 1997 May 01; 79(9):1647-55. PubMed ID: 9128978
    [Abstract] [Full Text] [Related]

  • 14. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P.
    Clin Cancer Res; 2008 Dec 01; 14(23):7813-21. PubMed ID: 19047109
    [Abstract] [Full Text] [Related]

  • 15. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 Dec 01; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 16. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
    Satoh H, Yagyu H, Sumi M, Ishikawa H, Hamada M, Suyama T, Naitoh T, Inoue M, Saitoh T, Uchida Y.
    Gan To Kagaku Ryoho; 1994 May 01; 21(6):795-9. PubMed ID: 7514388
    [Abstract] [Full Text] [Related]

  • 17. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W, Hoppe M, Muley T, Drings P.
    Anticancer Res; 1997 May 01; 17(4B):2875-8. PubMed ID: 9329552
    [Abstract] [Full Text] [Related]

  • 18. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
    Zissimopoulos A, Stellos K, Permenopoulou V, Petrakis G, Theodorakopoulos P, Baziotis N, Thalassinos N.
    Hell J Nucl Med; 2007 May 01; 10(1):62-6. PubMed ID: 17450257
    [Abstract] [Full Text] [Related]

  • 19. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR, Zhang X, Xu ZF, Zheng S.
    Ai Zheng; 2002 Feb 01; 21(2):196-9. PubMed ID: 12479076
    [Abstract] [Full Text] [Related]

  • 20. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma].
    Lorenz J, Gillmann-Blum D, Jensen M, Kreienberg R.
    Pneumologie; 1990 Nov 01; 44(11):1259-63. PubMed ID: 2177891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.